|
|
|
| The preventive effect of Celebrex on the acute phase of post-menopausal osteoporosis induced by zoledronic acid |
| XIAO Heng ZHAO Chenyang XIE Shiwei LI Quan |
| Department of Orthopaedics, Central Hospital of Panzhihua City, Sichuan Province, Panzhihua 617067, China |
|
|
|
Abstract Objective To analyze the clinical effect of Celebrex Prophylaxis Zoledronic Acid on acute phase response (APR) of postmenopausal osteoporosis (PMO). Methods From January 2016 to November 2018, 100 cases of postmenopausal osteoporosis (PMO) patients admitted to Panzhihua Central Hospital of Sichuan Province were selected. According to the random number table method, the patients were divided into control group and observation group, with 50 cases in each group. All patients were treated with Zoledronic Acid. In order to prevent APR caused by Zoledronic Acid, Acetaminophen was used as an intervention in the control group and Celebrex was used as an intervention in the observation group. The incidence rate of APR was observed in the two groups, and the pain degree of adverse reactions to musculoskeletal pain in the two groups were evaluated by visual analogue score (VAS), and the quality of life before and after intervention in the two groups were evaluated by the 16-item Chinese osteoporosis quality of life scale (COQOL-16). Results After the intervention, the incidence of influenza-like symptoms, incidence of fever, and incidence of musculoskeletal pain in the observation group were lower than those in the control group (P ＜ 0.05). On the 1st to 3rd day after intervention, the VAS scores of the musculoskeletal pain in the observation group were lower than those in the control group (P ＜ 0.05). On the 4th and 5th day statistically after intervention, there was no significant difference in VAS scores of musculoskeletal pain patients between the two groups of musculoskeletal pain patients (P ＞ 0.05). On the 3rd day, the COQOL-16 scores of the observation group were not significantly different from those before treatment (P ＞ 0.05), but lower than the control group, the difference was significant (P ＜ 0.05). Conclusion Celebrex can prevent APR caused by Zoledronic Acid in treating PMO, reduce the degree of musculoskeletal pain and fever, and not reduce the quality of life of patients.
|
|
|
|
|
|
[1] Black DM，Rosen CJ. Postmenopausal osteoporosis [J]. New Engl J Med，2016，374（3）：254-262.
[2] Miller PD，Pannacciulli N，Brown JP，et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates [J]. J Clin Endocr Metab，2016，101（8）：3163-3170.
[3] Dempster DW，Zhou H，Recker RR，et al. A longitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ trial [J]. J Bone Miner Res，2016，31（7）：1429-1439.
[4] Brune K，Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs [J]. J Pain Res，2015，8：105-118.
[5] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南（2011年）[J].中华骨质疏松和骨矿盐疾病杂志，2011，4（1）：2-17.
[6] 卞庆来，邹小娟，戴红，等.绝经后骨质疏松症患者舌象瘀斑指数与骨密度T值及骨痛VAS评分相关性探讨[J].中国骨质疏松杂志，2016，22（3）：326-329.
[7] 何藻鹏，杨德鸿，李丽.中国人骨质疏松症生存质量简明量表的编制与信效度[J].南方医科大学学报，2014（11）：1637-1641.
[8] 郑上团，吴斗，赵恩哲，等.股骨近端防旋转髓内钉固定联合应用唑来膦酸治疗骨质疏松性股骨转子间骨折的疗效[J].中华创伤杂志，2016，32（4）：320-324.
[9] 马文泽，李文成，丁尔勤.唑来膦酸对骨质疏松性骨折局部骨痂力学强度的影响[J].中国老年学杂志，2016，36（16）：58-60.
[10] 孟佳，王秋军，范鹰，等.双膦酸盐预治疗减少首次应用唑来膦酸不良反应的研究[J].中国骨质疏松杂志，2017， 23（7）：938-941.
[11] 关媛，高燕玲，李贵庆.唑来膦酸注射液治疗高龄老年性骨质疏松的药物不良反应发生情况研究[J].中国全科医学，2017，20（28）：3522-3526.
[12] Roelofs AJ，Jauhiainen M，M?觟nkk?觟nen H，et al. Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP [J]. Brit J Haematol，2009，144（2）：245-250.
[13] Kobayashi Y，Hiraga T，Ueda A，et al. Zoledronic acid delays wound healing of the tooth extraction socket，inhibits oral epithelial cell migration，and promotes proliferation and adhesion to hydroxyapatite of oral bacteria，without causing osteonecrosis of the jaw，in mice [J]. J Bone Miner Metab，2010，28（2）：165-175.
[14] 王柏松.观察唑来膦酸预防股骨头坏死塌陷的效果及作用机制[J].家庭心理医生，2015，11（1）：216-217.
[15] Tachibana I，Gehi D，Rubin CD. Treatment of Hypertrophic Osteoarthropathy With Underlying Pulmonary Adenocarcinoma Using Zoledronic Acid [J]. J Clin Rheumatol，2015，21（6）：333-334.
[16] 周淑兰，章志玲，梅志亮.唑来膦酸注射液治疗绝经后女性骨质疏松症不良反应的观察[J].实用临床医学，2015（1）：10-12.
[17] 张玲谦.唑来膦酸治疗老年骨质疏松患者不良反应的预防方法[J].中国医药，2013，8（11）：1615-1616.
[18] 李鲲，张坤，赵胜豪，等.唑来膦酸联合单侧穿刺PKP术治疗老年骨质疏松性椎体压缩性骨折的疗效及不良反应的预防[J].华中科技大学学报：医学版，2017，46（5）：600-603.
[19] 龚国梅，初紫晶，陈丽霞，等.经皮椎体成形术对老年骨质疏松性椎体压缩性骨折患者生存质量的影响[J].中国老年学杂志，2017，37（11）：2749-2750.
[20] 甘发荣，张泰标，胡万钧，等.补肾活血汤联合经皮椎体成形术治疗骨质疏松性胸腰椎压缩骨折的疗效分析[J].中国骨质疏松杂志，2018，24（4）:526-529，542.
[21] 黄淑纾，王军，林华.唑来膦酸治疗绝经后骨质疏松症的有效性和安全性[J].交通医学，2016，30（3）：218-222. |
|
|
|
